ENO1 and neoplasm: Since the tissue expression of the protein ENO1 did not differ significantly in the two EC subtypes, a potential mechanism accounting for decreased levels of circulating ENO1 in EAC patients could be a more prompt clearance of the immunocomplexes formed by ENO1/anti-ENO1 antibodies, released into the circulation during tumor growth.